Found 51 Solid Tumors trials
A listing of Solid Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel inhibitors of active, GTP-bound RAS (RAS[ON]), in combination with other anticancer therapies in patients with gastrointestinal solid tumors.
NP-G2-044 Monotherapy Primary Objectives The primary objectives for patients receiving NP-G2-044 monotherapy are the following: 1) to identify the recommended Phase 2 dose (RP2D) of continuously dosed NP-G2-044 monotherapy (Mono-RP2D) and characterize its safety; and 2) to assess preliminary signals of NP-G2-044 anti-tumor efficacy when administered as continuously dosed monotherapy.
This is a Phase 1/2, multicenter, open label, study of DCC-3116 as monotherapy, and in combination with trametinib, binimetinib, or sotorasib in patients with advanced or metastatic solid tumors with RAS/MAPK pathway mutation. The study consists of 2 parts, a dose-escalation phase, and an expansion phase.
This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur.
Please refer to Protocol Section 2 (Objectives and Endpoints). Please refer to Protocol Section 2 (Objectives and Endpoints). Please refer to Protocol Section 2 (Objectives and Endpoints).
Please refer to Protocol PRT3645-01, Section 5 (Objectives, Endpoints, and Estimands) Please refer to Protocol PRT3645-01, Section 5 (Objectives, Endpoints, and Estimands) Please refer to Protocol PRT3645-01, Section 5 (Objectives, Endpoints, and Estimands)
Please refer to Section 2 of the full protocol (Study Objectives) Please refer to Section 2 of the full protocol (Study Objectives) Please refer to Section 2 of the full protocol (Study Objectives)
This is an umbrella research study is designed to learn more about the safety and effectiveness of AMG 510 in combination with different investigational agents. Eligible subjects include adults with KRAS p.G12C Mutation.
The purpose of this study are to determine the maximum dose of FF-10832 that can be tolerated when taken in combination with pembrolizumab and to determine whether FF10832 taken by itself or in combination with pembrolizumab has anti-tumor activity.
